Company Overview and News

9
Eastmain Resources Announces C$5 Million Bought Deal Private Placement

2018-06-14 globenewswire
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
EANRF ER MALRY MALRF MIN GG

9
UPDATE: Eastmain Announces Robust Preliminary Economic Assessment and Updated Mineral Resource Estimate at the Eau Claire Project

2018-05-23 globenewswire
TORONTO, May 23, 2018 (GLOBE NEWSWIRE) -- Eastmain Resources Inc. (“Eastmain” or the “Company”) (TSX:ER) (OTCQX:EANRF) is reissuing this morning’s press release due to minor corrections of certain footnotes as requested by one of the Qualified Persons. These changes are non-material and do not impact any quantitative figures previously released.
EANRF ER MALRY MALRF MIN GG

9
Eastmain Announces Robust Preliminary Economic Assessment and Updated Resource Estimate at the Eau Claire Project

2018-05-23 globenewswire
TORONTO, May 23, 2018 (GLOBE NEWSWIRE) -- Eastmain Resources Inc. (“Eastmain” or the “Company”) (TSX:ER) (OTCQX:EANRF) is pleased to announce positive and robust results of a Preliminary Economic Assessment (“PEA”) on its 100%-owned Eau Claire Gold Project (“Eau Claire” or “Project”) located in James Bay, Québec. All figures are in Canadian dollars, unless stated.
EANRF ER MALRY MALRF MIN GG

9
Eastmain Announces Conference Call to Discuss Eau Claire PEA Expected May 23, 2018

2018-05-18 globenewswire
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Eastmain Resources Inc. (“Eastmain” or the “Company”) (TSX:ER) (OTCQX:EANRF) expects to announce results of its Preliminary Economic Assessment (“PEA”) on its 100%-owned Eau Claire project located in James Bay, Quebec on Wednesday, May 23, 2018 before market open.
EANRF ER MALRY MALRF MIN GG

5
Eastmain Reports Voting Results from Annual General Meeting

2018-04-27 globenewswire
TORONTO, April 27, 2018 (GLOBE NEWSWIRE) -- Eastmain Resources Inc. (“Eastmain” or the “Company”) (TSX:ER) (OTCQX:EANRF) has released the voting results from its annual general meeting held Thursday April 26, 2018, in Toronto, Ontario, in accordance with Toronto Stock Exchange requirements.
EANRF ER GG

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to TSX:ER / Eastmain Res J on message board site Silicon Investor.

Politics for Pros- moderated Buy and Sell Signals, and Other Market Perspectives
Franklin, Andrews, Kramer u0026 Edelstein Immunomedics (IMMU) - moderated
Formerly About Advanced Micro Devices View from the Center and Left
Politics for Conservatives A Real American President: Donald Trump
Liberalism: Do You Agree Weu0027ve Had Enough of It? 2026 TeoTwawKi ... 2032 Darkest Interregnum